Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron PharmafiledCriticalRegeneron Pharma
Publication of UY33631ApublicationCriticalpatent/UY33631A/en
Se proporcionan anticuerpos que se unen a CD48 y métodos de uso de los mismos. En ciertas realizaciones de la invención, los anticuerpos son anticuerpos completamente humanos que se unen a CD48 humano. En otras realizaciones, los anticuerpos de la invención bloquean la unión de CD48 a uno o más receptores de CD48. Estos anticuerpos son útiles, entre otros, para el tratamiento de enfermedades y trastornos asociados a una o más actividades biológicas de CD48, que incluyen el tratamiento de afecciones alérgicas y otras afecciones inflamatorias.Antibodies that bind to CD48 and methods of use thereof are provided. In certain embodiments of the invention, the antibodies are fully human antibodies that bind to human CD48. In other embodiments, the antibodies of the invention block the binding of CD48 to one or more CD48 receptors. These antibodies are useful, among others, for the treatment of diseases and disorders associated with one or more biological activities of CD48, which include the treatment of allergic conditions and other inflammatory conditions.
UY33631A2010-04-142011-09-27
ANTI-CD48 ANTIBODIES AND USES OF THE SAME
UY33631A
(en)